Abstract:337 Background: Prostate cancer remains the most common solid organ malignancy among males in the United States. Commercial biomarkers and multiparametric MRI have been utilized to better triage men with elevated PSA and determine patients most likely to have clinically significant prostate cancer (csPCa) upon prostate biopsy. We studied the combination of MRI with PSA-based and novel extracellular vesicle (EV)-based biomarkers to determine the optimal pre-biopsy testing to reduce the number of unnecessary biopsies. Methods: Men presenting to our clinic with elevated PSA (≥ 2 ng/ml) were prospectively enrolled from October 2019 to March 2022. All men underwent multiparametric MRI and blood draws to determine prostate health index (PHI) scoring, EV density, and PSA density. MRI-fusion biopsy was performed with both systematic and targeted prostate sampling, with clinicians blinded to prior blood testing results. Blood concentrations of prostate EV (ProsEVs) were measured by nanoscale flow cytometry using antibodies against PSMA and STEAP1. Sensitivity, specificity, positive predictive value, and negative predictive value were calculated, and receiver operator characteristic (ROC) curves were constructed separately for all patients, those without prior diagnosis of PCa, and biopsy-naïve patients. Bootstrapping analysis was performed to provide more accurate assessment of the predictive ability of all combinations. Results: Ultimately, 175 men enrolled and underwent MRI, blood testing, and prostate biopsy. Among the 175 patients included, 101 (58%) had never undergone biopsy, 38 (22%) had a previous negative biopsy, and 36 (21%) were on active surveillance (AS) for GS6 disease. AUC of mpMRI (PI-RADS≥3) to predict clinically significant PCa was 0.66 with a sensitivity, specificity, NPV and PPV of 95.2%, 37.6%, 76.0% and 79.26%. MRI combined with STEAP1-EV density had an AUC of 0.77 with a sensitivity, specificity, NPV and PPV of 90.1%, 46.7%, 64.4% and 80.9%. A multivariable model including MRI, STEAP1-EV density, PSA density and PHI density outperformed other combinations with an AUC, sensitivity, specificity, NPV and PPV of 0.90, 89.2%, 68.7%, 72.8% and 88.1%. Conclusions: Combination of mpMRI with ProsEV and PSA derivatives demonstrated better predictive ability for csPCa on biopsy compared to imaging or serum testing alone. Inclusion of prostate volume with biomarkers further increased predictive ability which could lead to a decrease in number of unnecessary biopsies for men with benign conditions and indolent cancer.

Diagnostic Performance of Prospectively Assigned Likert Scale Scores to Determine Extraprostatic Extension and Seminal Vesicle Invasion With Multiparametric MRI of the Prostate.

Prostate Imaging-Reporting and Data System Version 2 in Combination with Clinical Parameters for Prostate Cancer Detection: a Single Center Experience

Assessing Extraprostatic Extension with Multiparametric MRI of the Prostate: Mehralivand Extraprostatic Extension Grade or Extraprostatic Extension Likert Scale?

The Sensitivity and Specificity of Multiparametric Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Predicting Seminal Vesicle Invasion in Clinically Significant Prostate Cancer: A Multicenter Retrospective Study

[Use of Biopsy Results to Predict Capsular Perforation and Seminal Vesicle Invasion in Prostate Cancer].

Extra-prostatic extension (EPE) grading system: Correlation with MRI features and integration of capsular enhancement sign (CES) for “enhanced” detection of T3a lesions

Predictive Model Containing PI-RADS V2 Score for Postoperative Seminal Vesicle Invasion among Prostate Cancer Patients

Comparison of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and multi-parametric magnetic resonance imaging (MRI) in the evaluation of tumor extension of primary prostate cancer.

Evaluation of multiparametric MRI in predicting seminal vesicle invasion of prostate cancer

External validation of nomograms including MRI features for the prediction of side-specific extraprostatic extension

External Validation of the Extraprostatic Extension Grade on MRI and Its Incremental Value to Clinical Models for Assessing Extraprostatic Cancer

How can we identify Extraprostatic Extension (EPE) Before Surgery? The Use of a Preoperative Prostate MRI EPE Scoring System to Assess Post-Prostatectomy Locally Advanced Prostate Cancer

Development and comparison of a Chinese nomogram adding multi-parametric MRI information for predicting extracapsular extension of prostate cancer.

Prediction of Extraprostatic Extension in Patients with Clinically Organ-Confined Prostate Cancer.

Accuracy of MRI in detecting seminal vesicle invasion in prostate cancer: a systematic review and meta-analysis

MRI assessment of seminal vesicle involvement by prostate cancer using T2 signal intensity and volume

Diagnostic performance of prediction models for extraprostatic extension in prostate cancer: a systematic review and meta-analysis

The value of multiparametric MRI for predicting prostate cancer extracapsular extension

Prostate extracellular vesicles and prediction of clinically significant prostate cancer: A prospective single-institution pilot study.

Magnetic Resonance Elastography Combined With PI‐RADS v2.1 for the Identification of Clinically Significant Prostate Cancer

The Role of Multiparametric MRI (mpMRI) in the Prediction of Adverse Prostate Cancer Pathology in Radical Prostatectomy Specimen